Kirin Holdings’ LC-Plasma Study: A Potential Game-Changer in Preventing URTIs

Kirin Holdings Company, Limited ((KNBWY)) announced an update on their ongoing clinical study.

Study Overview: Kirin Holdings Company, Limited, in collaboration with RDC Clinical Pty Ltd, is conducting a study titled A Randomized Controlled Trial Evaluating the Efficacy of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria in Preventing Upper Respiratory Tract Infections and Reducing Symptom Severity and Duration. The study aims to assess the effectiveness of LC-Plasma in preventing upper respiratory tract infections (URTIs) among healthy volunteers, highlighting its potential significance in public health.

Intervention/Treatment: The study tests the dietary supplement LC-Plasma, administered as a 50mg tablet taken daily over 24 weeks. The intervention aims to prevent URTIs and reduce symptom severity and duration, compared to a placebo.

Study Design: This Phase 3 interventional study employs a randomized, parallel assignment model with quadruple masking. The primary purpose is prevention, ensuring unbiased results by masking participants, care providers, investigators, and outcomes assessors.

Study Timeline: The study began on February 10, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on June 22, 2025, indicating ongoing recruitment and progress.

Market Implications: This study update could positively influence Kirin Holdings’ stock performance by showcasing its commitment to innovative health solutions. Success in this trial may enhance investor confidence and position Kirin favorably against competitors in the dietary supplement market.

The study is ongoing, with further details available on the ClinicalTrials portal.